Virtual FDA AdComm for Alkermes' ALKS 3831 adds new focus on drug-drug interactions

Alkermes has a tentative fall date with a virtual FDA review committee that will focus on potential drug-drug interactions (DDIs) for its experimental schizophrenia and bipolar med.

The FDA has marked Oct. 9 as a “tentative” date for its new virtual AdComm format for Alkermes’ ALKS 3831 (olanzapine/samidorphan) and has told the biopharma it wants to focus on DDIs.